Get the Stockscreener App
58.07
1.34%
-0.79
Vaxcyte Inc stock is traded at $58.07, with a volume of 656.56K.
It is down -1.34% in the last 24 hours and up +3.31% over the past month.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
See More
Previous Close:
$58.86
Open:
$58.11
24h Volume:
656.56K
Relative Volume:
0.46
Market Cap:
$8.64B
Revenue:
-
Net Income/Loss:
$-946.53M
P/E Ratio:
-8.3357
EPS:
-6.9664
Net Cash Flow:
$-814.94M
1W Performance:
+0.00%
1M Performance:
+3.31%
6M Performance:
+7.34%
1Y Performance:
+84.76%
1-Day Range:
$57.30
$58.74
1-Week Range:
$57.30
$60.45
52-Week Range:
$29.87
$65.00
Vaxcyte Inc Stock (PCVX) Company Profile
Name
Vaxcyte Inc
Sector
Industry
Phone
650-837-0111
Address
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
58.07 | 8.88B | 0 | -946.53M | -814.94M | -6.9664 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Reiterated | Needham | Buy |
| Sep-12-25 | Initiated | Goldman | Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-24 | Initiated | Goldman | Buy |
| Dec-07-23 | Initiated | Mizuho | Buy |
| Apr-18-23 | Initiated | TD Cowen | Outperform |
| Jan-03-23 | Reiterated | Needham | Buy |
| Dec-15-22 | Initiated | Guggenheim | Buy |
| Nov-17-22 | Initiated | BTIG Research | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-24-21 | Resumed | Jefferies | Buy |
| Jul-07-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-07-20 | Initiated | Needham | Buy |
View All
Vaxcyte Inc Stock (PCVX) Latest News
Vaxcyte (NASDAQ:PCVX) Stock Rating Upgraded by Zacks Research - MarketBeat
(PCVX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Assenagon Asset Management S.A. Decreases Stock Holdings in Vaxcyte, Inc. $PCVX - MarketBeat
Janus Henderson Group (PCVX) discloses 18.0M-share Vaxcyte ownership stake - Stock Titan
Vaxcyte, Inc. (PCVX) Stock Analysis: Potential 87.70% Upside with Innovative Vaccine Pipeline - DirectorsTalk Interviews
Bank of America Corp DE Increases Position in Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte Inc (PCVX) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Vaxcyte (NASDAQ:PCVX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Janus Henderson Group (PCVX) discloses 65,694 Vaxcyte shares held for clients - Stock Titan
Needham Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $110 - Moomoo
The Manufacturers Life Insurance Company Trims Stock Position in Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte, Inc. $PCVX Shares Acquired by Dimensional Fund Advisors LP - MarketBeat
FMR LLC (PCVX) discloses 20.8M-share beneficial stake in Vaxcyte common stock - Stock Titan
TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $75 - Moomoo
PCVX SWOT Analysis: Key Financial Insights Revealed in 10-Q Fili - GuruFocus
Vaxcyte (NASDAQ:PCVX) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
Vaxcyte (NASDAQ:PCVX) Insider Harpreet Dhaliwal Sells 17,000 Shares - MarketBeat
Vaxcyte (PCVX) Advances Phase 3 Trials Amid Mixed Market Signals - GuruFocus
Vaxcyte, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Insider Selling: Vaxcyte (NASDAQ:PCVX) COO Sells 2,250 Shares of Stock - MarketBeat
Vaxcyte Q2 net loss widens on higher expenses - TradingView
Vaxcyte, Inc. Q2 2026: Net loss $(284.3M), EPS $(1.97) — 10-Q Summary - TradingView
PCVX: Phase 3 VAX-31 adult trials fully enrolled; OPUS-1 topline data expected Q4 2026 - TradingView
Vaxcyte (Nasdaq: PCVX) posts $605M YTD loss and $2.5B cash balance - Stock Titan
Vaxcyte reports $2.5B cash; Q2 net loss $284.3M, R&D up to $267.9M - TradingView
Vaxcyte, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Vaxcyte, Inc. SEC Filing (Aug 5, 2026) - Stock Titan
BRIEF-Vaxcyte Q2 Operating Expenses USD 302.777 Million - TradingView
Press Release: Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update - Moomoo
PCVX Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Vaxcyte (NASDAQ:PCVX) CFO Andrew Guggenhime Sells 10,000 Shares of Stock - MarketBeat
Vaxcyte, Inc. (NASDAQ:PCVX) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
PCVX (PCVX) holder plans August 3 sale after option exercise - Stock Titan
Vaxcyte, Inc. (PCVX) Stock Analysis: Unpacking The 101.55% Potential Upside - DirectorsTalk Interviews
PCVX (PCVX): insider Andrew Guggenhime plans 10,000-share stock sale - Stock Titan
Current ratio of Vaxcyte, Inc. – XETR:5VA - TradingView
DV Trading LLC Takes Position in Vaxcyte, Inc. $PCVX - MarketBeat
Liquidity Mapping Around (PCVX) Price Events - Stock Traders Daily
59,061 Shares in Vaxcyte, Inc. $PCVX Purchased by Stempoint Capital LP - MarketBeat
Vaxcyte Inc (PCVX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ADAR1 Capital Management LLC Trims Holdings in Vaxcyte, Inc. $PCVX - MarketBeat
Bank of New York Mellon Corp Has $27.57 Million Stock Holdings in Vaxcyte, Inc. $PCVX - MarketBeat
Grant Pickering (PCVX) outlines 18,198-share sale and recent June stock trades - Stock Titan
PCVX|Vaxcyte Inc|Price:55.720|Chg%:+1.060 - TradingKey
Vaxcyte Inc (PCVX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Vaxcyte, Inc. (PCVX) Stock Analysis: A 99% Potential Upside in a Clinical-Stage Vaccine Innovator - DirectorsTalk Interviews
First Light Asset Management LLC Takes Position in Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte Inc (PCVX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TradingKey - TradingKey
Vaxcyte Inc (PCVX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Vaxcyte Inc Stock (PCVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):